-

Robbins LLP Encourages VITL Stockholders to Contact the Firm for Information About the Class Action Against Vital Farms, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Vital Farms, Inc. (NASDAQ: VITL) securities between May 8, 2025 and February 26, 2026. Vital Farms purports to be an ethically minded food company that became the leading U.S. brand of pasture-raised eggs and second largest U.S. egg brand by retail dollar sales.

Robbins LLP is Investigating Allegations that Vital Farms, Inc. (VITL) Misled Investors Regarding its Business Prospects

Share

For more information, submit a formemail attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What is the class period? May 8, 2025 – February 26, 2026

What are the allegations? Robbins LLP is Investigating Allegations that Vital Farms, Inc. (VITL) Misled Investors Regarding its Business Prospects

According to the complaint, during the class period, defendants made false and misleading statements because: (1) defendants emphasized the importance of implementing the enterprise resource planning ("ERP") system to Vital Farms’ operations and that it was “fundamental to the operational improvements we are planning”; (2) stated the implementation of the ERP would require the time and attention of “management and key crew members”; (3) indeed, defendant Wrede stated that Vital Farms pushed back the expected implementation date of the ERP to “ensure flawless switchover”; (4) given the stated importance of and management’s knowledge of the issues surrounding the implementation of the ERP, defendants knew, or were reckless in not knowing, that implementing the ERP would result in delays of shipments and/or production; (5) defendants did not warn investors that implementing the ERP would result in delays in shipments and/or production, instead merely couching it as a hypothetical in their risk disclosures; and (6) as a result of the delay in shipments and/or production, Vital Farms would lose important retail shelf space, which would negatively impact Vital Farms’ business and operations.

Plaintiff alleges that on February 26, 2026, Vital Farms filed an annual report on a Form 10-K for the fiscal year ended December 28, 2025, revealing that Vital Farms’s revenue for fiscal year 2025 was $759,444,000, missing its guidance of $775,000,000. Furthermore, the Company missed the earnings per share (“EPS”) consensus, reporting EPS of $0.35 versus market consensus of $0.39. The 2025 10-K also revealed that the Company experienced "temporary disruptions in order and fulfillment levels following the launch date of the new ERP system.” On this news, Vital Farms stock declined by $2.68 per share, or 10.8%, to close at $22.11 on February 26, 2026.

What can shareholders do now? You may be eligible to participate in the class action against Vital Farms, Inc. Shareholders, who wish to serve as lead plaintiff for the class must submit their papers to the court by May 26, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Vital Farms, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:VITL

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom